Quick Links

Breadcrumbs Navigation

Home > Shared Resources > PK/PD Bioanalytical Core Lab > Select Publications

Jumbo Large Regular Text:

Select Publications

1. Spasojevic, I., Ludeman, S., O. M. Colvin, Warshany, K., Batinic-Haberle, I.,New approach to the activation of anti-cancer pro-drug by metallporphyrin-based cyt P450 mimics in all-aqueous biologically relevant system J. Inorg. Biochem. 2006, 100, 1897-1902 (IF 2.65).

2. Hauck, M.L., LaRue, S. M., Petros, W. P., Poulson, J. M., Yu, D., Spasojevic, I., Pruitt, A. F., Klein A., Case, B., Thrall, D. E., Needham, D., Dewhirst, M. W.,Phase I trial of doxorubicin-containing low temperature sensitive liposomes in spontaneous canine tumors, Clin. Cancer Res. 2006, 12, 4004-4010 (IF 6.18).

3. Spasojevic I, Yumin C, Noel, T, Yu I, Pole, MP, Zhang L, Zhao Y, St. Clair DK, Batinic-Haberle I, Mn porphyrin-based SOD mimic, MnTE-2-PyP5+ targets mouse heart mitochondria, Free Radic. Biol. Med., 2007, 42, 1193-1200.

4. Emmenegger, U., Shaked, Y., Man, S., Bocci, G., Spasojevic, I., Francia, G., Kouri, A., Coke, R., Cruz-Munoz, W., Ludeman, S. M., Colvin, O. M., Kerbel, R. S., Pharmacodynamic and pharmacokinetic study of chronic low-dose metronomic cyclophosphamide therapy in mice, Mol. Cancer Ther. 2007, 6, 2280-2289.

5. Vlahovic G, Ponce AM, Rabbani Z, Salahuddin FK, Zgonjanin L, Spasojevic I, Vujaskovic Z, Dewhirst MW, Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts. British J. Cancer 2007, 1-6 (IF 4.46).

6. Kleiter M. M., Yu D., Mohammadian L. A., Niehaus N., Spasojevic I., Sanders L., Viglianti B. L., Yarmolenko P. S., Hauck M., Petry N. A., Wong T. Z., Dewhirst M. W., Thrall D. E., A tracer dose of Technetium-99m-labeled liposomes can estimate the effect of hyperthermia on intratumoral Doxil extravasation, Clin. Cancer Res., 2006; 12(22): 6800 – 6807 (IF 6.18).

7. Horwitz M.E., Spasojevic I., Morris A., Telen M., Essel J., Gasparetto C. M., Sullivan, K., Long, G., Chute, J. Chao, N, David Rizzieri, D. Fludarabine-based Non-myeloablative Stem Cell Transplantation for a Patient with Sickle Cell Disease and Renal Failure: Clinical Outcome and Pharmacokinetic Comparison to Patients with Normal Renal Function, Biology of Blood and Marrow Transplantation 2007, 13, 1422-1426 (IF 3.458).

8. Rao, A. V., Younis, I. R., Sand, G. J., Spasojevic, I., Adams, D. J., Decastro, C. M., Gockerman, J. P., Peterson, B. L., Petros, W. P., Moore, J. O., Rizzieri, D. A.,Phase I evaluation of gemcitabine, mitoxantrone, and their effect on plasma disposition of fludarabine in patients with relapsed or refractory acute myeloid leukemia, Leuk. Lymphoma 2008, 49, 1523-1529 (IF 1.56).

9. Spasojevic, I., Chen, Y., Noel, T. J., Fan, P., Zhang, L., Reboucas, J. S., St. Clair, D. K., Batinic-Haberle, I, Pharmacokinetics of the potent redox modulating manganese porphyrin, MnTE-2-PyP5+ in plasma and major organs of B6C3F1 mice, Free Radic. Biol. Med. 2008, 45, 943-949.

10. McMahon N, Cheng TY, Beasley GM, Spasojevic I, Petros W, Augustine CK, Zipfel P, Padussis JC, Sanders G, Tyler DS. Optimizing melphalan pharmacokinetics in regional melanoma therapy: does correcting for ideal body weight alter regional response or toxicity? Ann Surg Oncol. 2009, 16:953-61.

11. Voora D, Shah SH, Spasojevic I, Ali S, Reed CR, Salisbury BA, Ginsburg GS.The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol. 2009 Oct 20;54(17):1609-16.

12. Kos, I., Reboucas, J. S., DeFreitas-Silva, G., Vujaskovic, Z., Dewhirst, M. W., Spasojevic, I., Batinic-Haberle, I, The effect of lipophilicity of porphyrin-based antioxidants. Comparison of ortho and meta isomers of Mn(III) N-alkylpyridylporphyrins,., Free Radic. Biol. Med. 2009, 47: 72–78.

13. Rabbani, Z. N., Spasojevic, I., Vasquez-Vivar, J., Haberle, S., Salvemini, D., Dewhirst, M. W., Vujaskovic, Z., Batinic-Haberle, I., Antiangiogenic action of redox-modulating Mn(III) meso-tetrakis(N-ethylpyridinium-2-yl)porphyrin, MnTE-2-PyP5+, via suppression of oxidative stress in a mouse model of breast tumor, Free Radic. Biol. Med. 2009, 47: 992–1004.

14. Il’yasova, D., Mixon G, Wang F, Marcom PK, Marks J, Spasojevic I,Craft N, Arredondo F, DiGiulio R. Markers of Oxidative Status in a Clinical Model of Oxidative Assault: a Pilot Study in Human Blood Following Doxorubicin Administration. Biomarkers, 2009, Aug, 14(5), 321-325 (2.20).

15. Spasojevic I., Kos I., Benov, L. T., Rajic Z., Fels, D., Dedeugd, D., Dewhirst, D. W. Reboucas, J. S., Vujaskovic, Z., Batinic-Haberle, I., Bioavailability of metalloporphyrin-based SOD mimics is greatly influenced by a single charge residing on a Mn site, Free Radic Res 2010, 45, 188-200, .DOI:10.3109/10715762.2010.522575.

16. Pretty JR, Connor TH, Spasojevic I, Kurtz KS, McLaurin JL, B' Hymer C, Debord DG Sampling and mass spectrometric analytical methods for five antineoplastic drugs in the healthcare environment. J Oncol Pharm Pract. 2010 Dec 23, PMID: 21183556.

17. Il'yasova D, Kennedy K, Spasojevic I, Wang F, Tolun AA, Base K, Young SP, Kelly Marcom P, Marks J, Millington DS, Dewhirst MW. Individual responses to chemotherapy-induced oxidative stress. Breast Cancer Res Treat. 2010, 125, 583-589. PMID: 20830514.

18. Yarmolenko PS, Zhao Y, Landon C, Spasojevic I, Yuan F, Needham D, Viglianti BL, Dewhirst MW.Comparative effects of thermosensitive doxorubicin-containing liposomes and hyperthermia in human and murine tumours. Int J Hyperthermia. 2010; 26(5):485-98.PMID: 20597627

19. Tailor TD, Hanna G, Yarmolenko PS, Dreher MR, Betof AS, Nixon AB, Spasojevic I, Dewhirst MW. Effect of pazopanib on tumor microenvironment and liposome delivery. Mol Cancer Ther. 2010, 9,1798-808

20. Il'yasova D, Spasojevic I, Wang F, Tolun AA, Base K, Young SP, Marcom PK, Marks J, Mixon G, DiGiulio R, Millington DS. Urinary biomarkers of oxidative status in a clinical model of oxidative assault. Cancer Epidemiol Biomarkers Prev. 2010, 19, 1506-10.

21. Batinic-Haberle I., Spasojevic I., Tse, HM, Tovmasyan A., St. Clair D. K., Vujaskovic, Z., Dewhirst M. W., Piganelli J. D. Design of Mn porphyrins for treating oxidative stress injuries and their redox-based regulation of cellular transcriptional activities. Amino Acids, 2010 doi: 10.1007/s726-010-0603-06. , invited review

22. Palmer GM, Boruta RJ, Viglianti BL, Lan L, Spasojevic I, Dewhirst MW., Non-invasive monitoring of intra-tumor drug concentration and therapeutic response using optical spectroscopy. J Control Release, 2010, 142, 457-64.

23. Osada T, Chen M, Yang XY, Spasojevic I, Vandeusen JB, Hsu D, Clary BM, Clay TM, Chen W, Morse MA, Lyerly HK. Anti-helminth compound niclosamide downregulates Wnt Signaling and elicits antitumor responses in tumors with activating APC mutations. Cancer Res. 2011 Apr 29, PMID: 21531761.

24. Reitman ZJ, Jin G, Karoly ED, Spasojevic I, Yang J, Kinzler KW, He Y, Bigner DD, Vogelstein B, Yan H. Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proc Natl Acad Sci U S A. 2011, Feb 22;108(8):3270-5.

25. Jin, G., Reitman, Z.J., Spasojevic, I., Batinic-Haberle, I., Yang, I., Schmidt-Kittler, O., Bigner, D., Yan, H. 2-hydroxyglutarate production, but not dominant negative activity, is shared by a panel of glioma-derived IDH1 R132 and IDH2 R172 mutants. PLOS One, 2011 Feb 4;6(2):e16812.

26. Sheng, H., Tse, H. M., Jung, J. Y., Zhang, Z., Spasojevic, I., Piganelli, J., Batinic-Haberle I., Warner, D. S., Neuroprotective Efficacy From Parenteral Administration Of A Redox-Modulating lipophilic MnPorphyrin, MnTHex-2-PyP5+ , J. Pharmacol. Exp. Ther. 2011, accepted - in press.

27. Spasojevic I, Ines Batinic-Haberle I. Superoxide dismutase mimics, in Principles of Free Radical Biomedicine, Kostas Pantopoulos and Hyman Schipper Eds., 2011, accepted - in press invited Book Chapter.